Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC

Transarterial therapy combined with bevacizumab plus immune checkpoint inhibitors as a neoadjuvant therapy for locally advanced HCC

BackgroundTransarterial therapy (TAT), bevacizumab (Bev), and immune checkpoint inhibitors (ICIs) have individually exhibited efficacy in treating advanced-stage hepatocellular carcinoma (HCC). This study aimed to assess the efficacy and safety of the combination of these three treatments as a neoad...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhenyun Yang, Qianyu Wang, Li Hu, Xiaoxian Sima, Juncheng Wang, Dandan Hu, Zhongguo Zhou, Minshan Chen, Yaojun Zhang, Yizhen Fu
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-12-01
Series:Frontiers in Immunology
Subjects:
hepatocellular carcinoma
neoadjuvant therapy
transarterial therapy
bevacizumab
immune checkpoint inhibitors
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1469302/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fimmu.2024.1469302/full

Similar Items